Sinovac boosters appear to increase antibodies -- which is good news. Sinovac booster shot reverses drop in antibody activities against Covid-19 Delta variant: Study https://www.straitstimes.com/asia/e...in-antibody-activities-against-covid-19-delta A booster dose of Sinovac Biotech's Covid-19 vaccine reversed a decline in antibody activities against the Delta variant, a study showed, easing some concerns about its longer-term immune response to the highly contagious strain of the virus. The study comes amid concerns about the Chinese vaccine's efficacy against Delta, which has become the dominant variant globally and is driving a surge in new infections even in the most vaccinated countries. Several countries which have relied heavily on the Sinovac vaccine have begun giving booster shots developed by Western manufacturers to people fully vaccinated with the Chinese shot. Neutralising antibody activities against Delta were not detected in samples taken from vaccine recipients six months after they received the second dose of Sinovac's CoronaVac vaccine, according to the study published on Sunday (Sept 5) before a peer review. But recipients of booster shots showed over 2.5-fold higher neutralising potency against Delta about four weeks after the third dose, compared with the level seen about four weeks after the second shot, researchers from Chinese Academy of Sciences, Furan University, Sinovac, and other Chinese institutions said in the paper. They did not discuss how specifically changes in antibody activity will affect Sinovac shot's efficacy in preventing people from getting sick from the variant. The lab study involves samples from 66 participants, including 38 volunteers who received either two or three doses of the vaccine. The World Health Organisation plans to ship around 100 million doses of the Sinovac and Sinopharm Covid-19 shots by the end of this month, mostly to Africa and Asia, in its first delivery of Chinese vaccines. But some countries rejected accepting the vaccines, citing lack of data on their effectiveness against Delta. Around 1.8 billion doses of the Sinovac vaccine have been supplied globally including China by end August, according to the company.
In world first, Cuba starts COVID-19 shots for toddlers Nation is using home-grown vaccines not recognized by the World Health Organization https://www.timesofisrael.com/in-world-first-cuba-starts-covid-19-shots-for-toddlers/ Cuba on Monday became the first country in the world to vaccinate children from the age of two against COVID-19, using home-grown shots not recognized by the World Health Organization. The communist island of 11.2 million people aims to inoculate all its children before reopening schools that have been closed for the most part since March 2020. The new school year started on Monday, but from home via television programs, as most Cuban homes do not have internet access. Having completed clinical trials on minors with its Abdala and Soberana vaccines, Cuba kicked off its inoculation campaign for children on Friday, starting with those 12 and older. On Monday, it started distributing shots in the 2-11 age group in the central province of Cienfuegos. Several other countries in the world are vaccinating children from the age of 12, and some are conducting trials in younger kids. Countries such as China, the United Arab Emirates and Venezuela have announced they plan to vaccinate younger children, but Cuba is the first to do so. Chile on Monday approved the Chinese Sinovac vaccines for children between six and 12. The Cuban vaccines, the first developed in Latin America, have not undergone international, scientific peer review. They are based on recombinant protein technology — the same used by the United States’ Novavax and France’s Sanofi shots also awaiting WHO approval. Unlike many other shots in use, recombinant vaccines do not require extreme refrigeration. The majority of schools in Cuba have been closed since March 2020, reopening for a few weeks at the end of last year before closing again in January. The government has announced schools will reopen gradually, in October and November, but only after all children have been vaccinated. UN agency UNICEF has called for schools worldwide to reopen as soon as possible, as “the long-term costs of closures are too high and hard to justify.” Cuba has seen an explosion in coronavirus infections in recent months, putting pressure on its health system. Of the 5,700 coronavirus deaths recorded since the outbreak started, nearly half were in the last month alone, as were almost a third of all reported cases.
U.S. Reaches 75% of Adults With at Least One Vaccine Dose https://www.bloomberg.com/news/arti...s-75-of-adults-with-at-least-one-vaccine-dose
vaz nazi's have been arguing with dated stale stats.... as the vaccines' protections wane. Their are arguments were either moronic or deliberately deceptive. At the moment we have a dynamic situation... vax nazi morons should be aware that what the claimed last month is now garbage and next month could be worse if the trends hold.
Because science. https://www.thecollegefix.com/despi...-covid-cases-than-it-did-this-time-last-year/ Despite 95% vaccination rate, Cornell today has five times more COVID cases than it did this time last year
Pfizer picked a COVID-19 vaccine dose far lower than Moderna's to minimize side effects, its top scientist says https://www.businessinsider.com/pfizer-lower-dose-moderna-covid-19-vaccine-fewer-side-effects-2021-9 Pfizer's top scientist said the company chose a relatively low vaccine dose to minimize side effects. Pfizer's vaccine has 30 micrograms of mRNA, the active ingredient. Moderna's has 100 micrograms. Both vaccines produce similar side effects, according to the CDC. Pfizer's top scientist has defended the dose of the company's COVID-19 vaccine, which is lower than in Moderna's vaccine. Pfizer's COVID-19 vaccine has 30 micrograms of mRNA, the active ingredient of the vaccine, and Moderna's has 100 micrograms. Scientists have speculated this could be a reason why Pfizer's shot produced a lower antibody response than Moderna's in recent studies. Philip Dormitzer, chief scientific officer at Pfizer, told the Financial Times on Wednesday that Pfizer and co-developer BioNTech "used the minimum dose level" that they could to get an immune response that was stronger than simply catching COVID-19. Dormitzer added that a higher dose might have risked more side effects, per the Financial Times. "If you look at what's going on with all the COVID-19 vaccines out there, the derailer has often been adverse events that have cropped up," he said. Pfizer and Moderna's COVID-19 vaccines produce similar side effects, according to the Centers for Disease Control and Prevention. Possible side effects include: a sore, painful, red arm; muscle aches; fatigue; and fever. A type of heart inflammation, called myocarditis, is an "extremely rare" side effect of both vaccines, and resolves quickly. There are case reports of so-called "Moderna arm," an angry red rash that goes away on its own after getting Moderna's shot, which isn't seen with Pfizer's. Insider contacted Moderna for comment, but didn't immediately receive a response. In the US, more than 214 million doses of Pfizer's shot have been given out, and 147 million of Moderna's, according to the CDC. Moderna shot boosted antibodies higher than Pfizer's A study of 1,600 Belgian health workers published as a research letter in JAMA on August 30 found that Moderna's COVID-19 vaccine produced twice as many antibodies compared with Pfizer's, at six to ten weeks after vaccination. The study authors said that the higher mRNA levels in Moderna's vaccine compared with Pfizer's, and the longer time interval between doses for Pfizer "might explain this difference." Another study from the University of Virginia, published as a research letter in JAMA on September 2, found there was no difference in antibody response between age groups with Moderna's vaccine, but that Pfizer's produced a lower antibody response in people aged 50 and older. The researchers said that the differences between the vaccines could "relate" to the amount of mRNA in them. The antibody response is just one aspect of the immune system, and the antibody level needed to protect against COVID-19 is not yet established. Vaccine protection also depends on whether or not the antibody response changes over time. For example, a recent study from Oxford University found that at four months, Pfizer's and AstraZeneca's vaccines had similar levels of antibodies, because the antibody level from Pfizer's shot waned over time while the levels from AstraZeneca's remained the same. Previous real-world data from Canada found that after one dose, Pfizer's vaccine was 56% effective against COVID-19 with symptoms caused by the highly infectious Delta variant. Moderna's was 72% effective, the study found. Other factors could have influenced the results though, including that Pfizer's vaccine had typically been given to older people who tend to produce weaker immune responses. The study hasn't been scrutinized by experts in a peer-review.